Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R2 | Q9NPC1 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | BDKRB1 | P46663 | 3/20 | 0.43 |
| ▸ | PLK1 | P53350 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.42 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CFD | P00746 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MYC | P01106 | 1/20 | 0.39 |
| ▸ | WDR5 | P61964 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MME | P08473 | 1/20 | 0.38 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.38 |
| ▸ | CDK4 | P11802 | 1/20 | 0.38 |
| ▸ | CCND1 | P24385 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7960903 | 0.91 | BDKRB1 (0.47) | L3MBTL1BDKRB1POLBHPGDUSP2 | |
| SCHEMBL8419112 | 0.78 | L3MBTL1 (0.45) | LTB4R2L3MBTL1POLBHPGDCYP2C9 | |
| SCHEMBL9034499 | 0.77 | BDKRB1 (0.46) | LTB4R2L3MBTL1BDKRB1POLBAGTR1 | |
| SCHEMBL3977067 | 0.77 | LTB4R2 (0.43) | LTB4R2BDKRB1PLK1AGTR1AGTR2 | |
| SCHEMBL3974833 | 0.76 | ALDH1A1 (0.42) | L3MBTL1BDKRB1AGTR1AGTR2HPGD | |
| SCHEMBL3977563 | 0.76 | BDKRB1 (0.52) | BDKRB1HPGDKDM4EALDH1A1MYC | |
| SCHEMBL3976517 | 0.75 | BDKRB1 (0.48) | BDKRB1HPGDKDM4EALDH1A1MYC | |
| SCHEMBL3982611 | 0.74 | ALDH1A1 (0.43) | L3MBTL1BDKRB1AGTR1AGTR2HPGD | |
| SCHEMBL3978885 | 0.73 | BDKRB1 (0.49) | BDKRB1HPGDKDM4EALDH1A1MYC | |
| SCHEMBL9339237 | 0.71 | PPARG (0.46) | AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538133-B2 | Benzimidazole derivatives, their production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-26 | — | — | US | disclosed |
| US-20070259932-A1 | angiotensin II antagonists; Hypotensive agents; cardiovascular disorders; reacting Ethyl 1-[(2'-cyanobiphenyl-4-yl)methyl]-2-mercaptobenzimidazole-7-carboxylic acid compound with alkylating agent | TAKEDA PHARMACEUTICAL COMPANY, LIMITED | 2007-11-08 | — | — | US | disclosed |
| US-7153972-B2 | Benzimidazole derivatives, their production and use | TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2006-12-26 | — | — | US | disclosed |
| US-20050131039-A1 | Benzimidazole derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. | 2005-06-16 | — | — | US | disclosed |
| US-6844443-B2 | Benzimidazole derivatives, their production and use | TAKEDA PHARMACEUTICAL COMPANY, LTD. (JP) | 2005-01-18 | — | — | US | disclosed |
| US-20040044223-A1 | Benzimidazole derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. | 2004-03-04 | — | — | US | disclosed |
| US-6608210-B2 | Such as 1-(cyclohexyloxycarbonyloxy)ethyl-2-ethoxy-1-((2'-(1H-tetrazol-t-yl)biphenyl-4-yl)methyl) benzimidazol-7-carboxylate; exhibits antihypertensive activity and strong angiotensin II antagonistic activity | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-08-19 | — | — | US | disclosed |
| EP-0720982-B1 | Benzimidazole derivatives, their production and use and use as angiotensin II antagonists | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2002-11-13 | — | — | EP | disclosed |
| US-20020151723-A1 | Benzimidazole derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. | 2002-10-17 | — | — | US | disclosed |
| US-6355808-B2 | ANGAGONIZING ANGIOTENSIN II | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-03-12 | — | — | US | disclosed |
| US-20010047020-A1 | Benzimidazole derivatives, their production and use | TAKEDA PHARAMCEUTICAL COMPANY, LIMITED (JP) | 2001-11-29 | — | — | US | disclosed |
| EP-0720982-A1 | Benzimidazole derivatives, their production and use and use as angiotensin II antagonists | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-07-10 | — | — | EP | disclosed |
| EP-0459136-A1 | Benzimidazole derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1991-12-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259932-A1 | angiotensin II antagonists; Hypotensive agents; cardiovascular disorders; reacting Ethyl 1-[(2'-cyanobiphenyl-4-yl)methyl]-2-mercaptobenzimidazole-7-carboxylic acid compound with alkylating agent | AGTR1, REN, AGTR2 | LTB4R2 2676/4885L3MBTL1 1880/4885BDKRB1 404/4885 |
| US-20050131039-A1 | Benzimidazole derivatives, their production and use | MRM1, CARM1, H1-4 | LTB4R2 2654/4885L3MBTL1 1310/4885BDKRB1 1089/4885 |
| US-20040044223-A1 | Benzimidazole derivatives, their production and use | HAT1, MRM1, H1-4 | LTB4R2 3222/4885L3MBTL1 1273/4885BDKRB1 1666/4885 |
| US-20020151723-A1 | Benzimidazole derivatives, their production and use | HAT1, MRM1, NSD1 | LTB4R2 3087/4885L3MBTL1 1135/4885BDKRB1 1539/4885 |
| US-20010047020-A1 | Benzimidazole derivatives, their production and use | REN, AGTR1, H1-3 | LTB4R2 3309/4885L3MBTL1 2421/4885BDKRB1 280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.